Altimmune, Inc. (ALT)
| Previous Close | 7.72 |
| Open | 7.65 |
| Bid | 7.36 x 200 |
| Ask | 7.48 x 800 |
| Day's Range | 7.38 - 7.81 |
| 52 Week Range | 2.09 - 14.84 |
| Volume | |
| Avg. Volume | 4,554,519 |
| Market Cap | 526.546M |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.66 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 20, 2017 |
| 1y Target Est | 21.86 |
GlobeNewswireAltimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2
- GlobeNewswire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences Conference (New York, NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern Time UBS Obesity Therapeutics Day (Virtual Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m. Eastern Time The s
- GlobeNewswire
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.alti
